Vol. 3, Issue 1, Part A (2021)

Fenofibrate an antilipidemic drug belonging to BCS class II, has very low oral bioavailability. Many approaches have been reported in literature and we selected a simple approach of formulating co-crystals to enhance the dissolution and subsequently bioavailability of fenofibrate. After reporting conformer screening, preparation and in-vitro evaluation of tartaric acid fenofibrate co-crystals as separate research work, formulation and in-vivo studies were undertaken in this work and an attempt to develop in-vitro in-vivo correlation was made using deconvolution and time scaling approach.